Email this article Nivolumab in treatment of relapsed Hodgkin lymphoma
- Authors: Valiev T.T.1,2, Odzharova A.A.1
-
Affiliations:
- N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
- I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
- Issue: Vol 2, No 2 (2022)
- Pages: 38-44
- Section: NEW DIRECTIONS AND ADVANCEMENTS IN TREATMENT OF ONCOLOGICAL DISEASES IN THE CURRENT AGE
- Published: 02.06.2022
- URL: https://mdonco.abvpress.ru/jour/article/view/35
- DOI: https://doi.org/10.17650/2782-3202-2022-2-2-38-44
- ID: 35
Cite item
Full Text
Abstract
The incidence of Hodgkin lymphoma (HL) relapses is 8-30 % and depend on disease stage, presence of unfavorable prognostic factors and treatment programme. Modern second-line treatment programmes are based on gemcitabine and carboplatin with following autologous stem cell transplantation and can reach many-year overall survival in 70 % of patients. For increasing treatment efficacy of relapsed HL monoclonal antibodies (brentuximab vedotin) and checkpoint inhibitors (nivolumab) are supplemented. Nowadays it makes an assessment of immunochemotherapy efficacy in patients with relapsed HL, determines long-term effects of treatment. Nevertheless, preliminary results allow to find a significant therapeutic advantages of immunochemotherapy with following autologous stem cell transplantation above standard polychemotherapy.
About the authors
T. T. Valiev
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Author for correspondence.
Email: timurvaliev@mail.ru
ORCID iD: 0000-0002-1469-2365
Timur T. Valiev.
24 Kashirskoe shosse, Moscow 115478; Bld. 2, 8 Trubetskaya St., Moscow 119991.
Russian FederationA. A. Odzharova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
ORCID iD: 0000-0003-3576-6156
24 Kashirskoe shosse, Moscow 115478.
Russian FederationReferences
- Belyaeva E.S., Susuleva N.A., Valiev T.T. The importance of intensive chemotherapy for advanced Hodgkin lymphoma in children. RMJ. Mat' i ditya = Russian Journal of Woman and Child Health 2020;3(2):149-53. (In Russ.). doi: 10.32364/2618-8430-2020-3-2-149-154.
- Valiev T.T., Belyaeva E.S. Results of longstanding, single-center trial for pediatric Hodgkin lymphoma treatment. Onkogematologiya = Oncohematology 2021;16(3):95-104. (In Russ.). doi: 10.17650/1818-8346-202116-3-95-104.
- Moskowitz C.H., Matasar M.J., Zelenetz A.D. et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, noncrossresistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood 2012;119(7):1665-70. doi: 10.1182/blood-2011-10-388058.
- Guidelines for the treatment of Hodgkin lymphoma. Ed. by E.A. Demina. Moscow: Gruppa Remedium, 2018. 72 p. (In Russ.).
- Kaloyannidis P., Hertzberg M., Webb K. et al. Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation. Br J Haematol 2019;188(4):540-9. doi: 10.1111/bjh.16201.
- Kewalramani T., Nimer S.D., Zelenetz A.D. et al. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 2003;32(7):673-9. doi: 10.1038/sj.bmt.1704214.
- Armand P., Engert A., Younes A. et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 Trial. J Clin Oncol 2018;36(14):1428-39. doi: 10.1200/JCO.2017.76.0793.
- Borchmann P., Goergen H., Kobe C. et al. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet 2017;390(10114):2790-802. doi: 10.1016/S0140-6736(17)32134-7.
Supplementary files
